The FDA is moving to ban compounded versions of semaglutide and tirzepatide, cutting off the primary revenue source for telehealth weight-loss platforms like TomorrowsRx. The agency's intent to restrict compounding follows improved supply of brand-name Ozempic, Wegovy, and Mounjaro.
Compounding pharmacies can legally produce copies of patented drugs only during shortage periods under FDA rules. TomorrowsRx and competitors including Hims & Hers, Ro, and Henry Meds built subscription models around $200-$400 monthly compounded GLP-1 prescriptions, undercutting $900-$1,300 brand prices.
The regulatory threat carries catastrophic business risk. TomorrowsRx's platform connects patients with physicians for weight management consultations, but compounded medications drive the economics. Without compounding access, the company must either negotiate wholesale agreements with Novo Nordisk and Eli Lilly or pivot entirely.
Novo Nordisk reported restored Wegovy supply in Q4 2025. Eli Lilly increased Mounjaro manufacturing capacity 50% in 2025. These improvements give FDA grounds to declare shortages resolved, triggering the compounding ban.
The timing pressures telehealth valuations. Hims & Hers stock dropped 17% in January 2026 on FDA compounding concerns. Investors are repricing growth assumptions as the regulatory window closes. TomorrowsRx faces similar valuation compression if unable to demonstrate a post-compounding revenue model.
Three paths remain: negotiate brand partnerships, shift to other compound-eligible drugs, or exit weight management. Brand partnerships require manufacturer cooperation and slash margins. Other compounded medications lack GLP-1 demand. Pivoting away from weight loss abandons established patient bases and marketing investments.
The FDA has not announced a formal timeline, but agency statements indicate action within 2026. Companies have months, not years, to restructure. Those without alternative revenue streams face existential pressure as compounding legality evaporates.
The crackdown reflects FDA prioritization of patent protections and safety oversight over telehealth access models. For TomorrowsRx, regulatory risk has escalated from theoretical to imminent.